Literature DB >> 34328111

Phytochemicals as regulators of Th17/Treg balance in inflammatory bowel diseases.

Yaoyao Chang1, Lixiang Zhai2, Jiao Peng3, Haiqiang Wu1, Zhaoxiang Bian2, Haitao Xiao4.   

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory intestinal disorder that is difficult to cure and characterized by periods of relapse. To face the challenges of limited treatment strategies and drawbacks of conventional medications, developing new and promising strategies as well as safe and effective drugs for treatment of IBD has become an urgent demand for clinics. The imbalance of Th17/Treg is a crucial event for the development of IBD, and studies have verified that correcting the imbalance of Th17/Treg is an effective strategy for preventing and treating IBD. Recently, a growing body of studies has indicated that phytochemicals derived from natural products are potent regulators of Th17/Treg, and exert preferable protective benefits against colonic inflammation. In this review, the great potential of anti-colitis agents derived from natural products through targeting Th17/Treg cells and their action mechanisms for the treatment or prevention of IBD in recent research is summarized, which may help further the development of new drugs for IBD treatment.
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Action mechanism; Alpinetin (PubChem CID: 154279); Arctigenin (PubChem CID: 64981); Baicalin (PubChem CID: 64982); Berberine (PubChem CID: 2353); Cambogin (PubChem CID: 11135781); Curcumin (PubChem CID: 969516); Dihydroartemisinin (PubChem CID: 3000518); Epigallocatechin gallate (PubChem CID: 65064); Icariin (PubChem CID: 5318997); Indirubin (PubChem CID: 10177); Indole-3-carbinol (PubChem CID: 3712); Inflammatory bowel disease (IBD); Isoliquiritigenin (PubChem CID: 638278); Mangiferin (PubChem CID: 5281647); Naringenin (PubChem CID: 932); Norisoboldine (PubChem CID: 14539911); Paeoniflorin (PubChem CID: 442534); Phytochemicals; Resveratrol (PubChem CID: 445154); Tangeretin (PubChem CID: 68077); Tetrandrine (PubChem CID: 73078); Th17/Treg balance; Therapeutic effects; diindolylmethane (PubChem CID: 3071)

Mesh:

Substances:

Year:  2021        PMID: 34328111     DOI: 10.1016/j.biopha.2021.111931

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Peptide YY 3-36 attenuates trinitrobenzene sulfonic acid-induced colitis in mice by modulating Th1/Th2 differentiation.

Authors:  Zhiqiang Li; Xiaoyuan Kuang; Tao Chen; Tao Shen; Jiahong Wu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

2.  Development of a naringenin microemulsion as a prospective ophthalmic delivery system for the treatment of corneal neovascularization: in vitro and in vivo evaluation.

Authors:  Yu Ma; Jingjing Yang; Yali Zhang; Chunyan Zheng; Zhen Liang; Ping Lu; Fei Song; Yuwei Wang; Junjie Zhang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

3.  P2Y1R Ligation Suppresses Th17 Cell Differentiation and Alleviates Colonic Inflammation in an AMPK-Dependent Manner.

Authors:  Yao-Yao Chang; Qiu-Chan Huan; Jiao Peng; Wen-Chun Bi; Li-Xiang Zhai; Yan Chen; Jonathan R Lamb; Xiang-Chun Shen; Zhao-Xiang Bian; Hai-Qiang Wu; Yong-Xian Cheng; Hai-Tao Xiao
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

Review 4.  Traditional Chinese Medicine Regulates Th17/Treg Balance in Treating Inflammatory Bowel Disease.

Authors:  Fengjiao Xie; Qin Xiong; Yilin Li; Chengjiao Yao; Ruike Wu; Qiuxiang Wang; Lihong Luo; Hongling Liu; Peimin Feng
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-15       Impact factor: 2.650

5.  Curcumin regulates the homeostasis of Th17/Treg and improves the composition of gut microbiota in type 2 diabetic mice with colitis.

Authors:  Qiu-Ping Xiao; You-Bao Zhong; Zeng-Ping Kang; Jia-Qi Huang; Wei-Yan Fang; Si-Yi Wei; Jian Long; Shan-Shan Li; Hai-Mei Zhao; Duan-Yong Liu
Journal:  Phytother Res       Date:  2022-03-02       Impact factor: 6.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.